お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
お問い合わせ
会社概要
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
997863

結核治療薬の世界市場

Tuberculosis Therapeutics
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 268 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=112.06円

ご注意：Single user licenseはDRM（デジタル著作権管理システム）付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

結核治療薬の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 268 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の結核治療薬の市場規模は、分析期間（2020年～2027年）に3.6％のCAGRで成長する見通しで、2020年の9億7,900万米ドルから、2027年には13億米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つであるアクティブTBは、分析期間中に4％のCAGRで成長し、7億7,760万米ドルに達すると予測されています。

当レポートは、世界の結核治療薬市場について調査しており、市場シェア、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Panacea Biotec Ltd.
  • Pfizer, Inc.

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と推進要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

IV. 競合

  • 企業プロファイル：37社
目次
Product Code: MCP-6337

Abstract:

Global Tuberculosis Therapeutics Market to Reach $1.3 Billion by 2027

Amid the COVID-19 crisis, the global market for Tuberculosis Therapeutics estimated at US$979 Million in the year 2020, is projected to reach a revised size of US$1.3 Billion by 2027, growing at aCAGR of 3.6% over the period 2020-2027. Active TB, one of the segments analyzed in the report, is projected to record 4% CAGR and reach US$777.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Latent TB segment is readjusted to a revised 3.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $264.1 Million, While China is Forecast to Grow at 6.5% CAGR

The Tuberculosis Therapeutics market in the U.S. is estimated at US$264.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$265.6 Million by the year 2027 trailing a CAGR of 6.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.1% and 2.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Select Competitors (Total 37 Featured) -

  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Panacea Biotec Ltd.
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Tuberculosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Active TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Active TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Active TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Latent TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Latent TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Latent TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for First-Line Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for First-Line Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for First-Line Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Second-Line Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Second-Line Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Second-Line Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 16: USA Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 17: USA Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: USA 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 19: USA Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 22: Canada Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: Canada Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: Canada 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 25: Canada Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 28: Japan Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Japan Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Japan 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 31: Japan Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 34: China Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: China Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: China 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 37: China Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: China Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: China 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 40: Europe Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 41: Europe Historic Review for Tuberculosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Europe 15-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 43: Europe Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Europe Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Europe 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 46: Europe Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 49: France Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: France Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: France 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 52: France Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: France Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: France 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 55: Germany Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Germany Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Germany 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 58: Germany Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Germany Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Germany 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 61: Italy Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Italy Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Italy 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 64: Italy Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Italy Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Italy 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 67: UK Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: UK Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: UK 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 70: UK Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: UK Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: UK 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 73: Spain Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Spain Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Spain 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 76: Spain Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Spain Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Spain 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 79: Russia Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Russia Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Russia 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 82: Russia Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Russia Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Russia 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 85: Rest of Europe Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of Europe Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of Europe 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 88: Rest of Europe Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of Europe Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of Europe 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 91: Asia-Pacific Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 92: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Asia-Pacific 15-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 94: Asia-Pacific Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Asia-Pacific 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 97: Asia-Pacific Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Asia-Pacific 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 100: Australia Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Australia Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Australia 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 103: Australia Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Australia Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Australia 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 106: India Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: India Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: India 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 109: India Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: India Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: India 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 112: South Korea Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: South Korea Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: South Korea 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 115: South Korea Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: South Korea Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: South Korea 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 118: Rest of Asia-Pacific Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Rest of Asia-Pacific Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 121: Rest of Asia-Pacific Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of Asia-Pacific Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 124: Latin America Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 125: Latin America Historic Review for Tuberculosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Latin America 15-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 127: Latin America Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Latin America Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Latin America 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 130: Latin America Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Latin America Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Latin America 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 133: Argentina Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Argentina Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Argentina 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 136: Argentina Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Argentina Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Argentina 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 139: Brazil Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Brazil Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Brazil 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 142: Brazil Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Brazil Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Brazil 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 145: Mexico Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Mexico Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Mexico 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 148: Mexico Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Mexico Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Mexico 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 151: Rest of Latin America Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Rest of Latin America Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Rest of Latin America 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 154: Rest of Latin America Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Rest of Latin America Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Rest of Latin America 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 157: Middle East Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 158: Middle East Historic Review for Tuberculosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Middle East 15-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 160: Middle East Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Middle East Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Middle East 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 163: Middle East Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Middle East Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Middle East 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 166: Iran Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Iran Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Iran 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 169: Iran Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Iran Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: Iran 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 172: Israel Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Israel Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: Israel 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 175: Israel Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Israel Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Israel 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 178: Saudi Arabia Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Saudi Arabia Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: Saudi Arabia 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 181: Saudi Arabia Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Saudi Arabia Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Saudi Arabia 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 184: UAE Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: UAE Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: UAE 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 187: UAE Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: UAE Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: UAE 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 190: Rest of Middle East Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Middle East Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: Rest of Middle East 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 193: Rest of Middle East Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Middle East Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of Middle East 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 196: Africa Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Africa Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Africa 15-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2020 & 2027
    • TABLE 199: Africa Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Africa Historic Review for Tuberculosis Therapeutics by Therapy - First-Line Therapy and Second-Line Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Africa 15-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line Therapy and Second-Line Therapy for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 37
株式会社グローバルインフォメーション
電話
044-952-0102
9:00-18:00 (土日・祝日を除く)
© Copyright 1996-2021, Global Information, Inc. All rights reserved.